On Monday, in a statement Roche said, it has entered into a $1.15 billion licensing deal with Sarepta Therapeutics to obtain the right to launch and commercialize Sarepta’s investigational gene therapy for Duchenne muscular dystrophy (DMD) outside the United States.
Roche will be making an upfront payment of $750 million in cash and $400 million in equity after the closing of Sarepta’s investigational micro-dystrophin gene therapy SRP-9001, which is currently in clinical development, said the the Swiss drugmaker.
The agreement also sees Sarepta being eligible to receive up to $1.7 billion in regulatory and sales milestones, along with royalties on net sales, said Roche.
The agreement is expected to close in the first quarter of 2020.
Sarepta will continue to be responsible for the clinical development and manufacturing of SRP-9001 while sharing global clinical development costs equally with Roche.
DMD is a rare degenerative neuromuscular disorder, which affects around one in 3,500-5,000 male child worldwide and causes severe progressive muscle loss and premature death, said Roche.